Cell transfection and luciferase reporter (DLR) assay

WW Wensheng Wang
RL Rongxiang Lv
JZ Jingjing Zhang
YL Yu Liu
ask Ask a question
Favorite

miR-29c-3p mimics (including miR control, cat. no. HMI0439, concentration: ≥106 TU/ml), miR-29c-3p inhibitor (including miR-29c-3p inhibitor NC, cat. no. HSTUD0440, concentration: ≥106 TU/ml) were purchased from Sigma-Aldrich (Shanghai) Trading Co., Ltd., shNC (cat. no. C01001, concentration: 108 TU/ml), sh-circ (cat. no. C03002, concentration: 108 TU/ml), pcDNA empty vector (cat. no. G01001, concentration: 108 TU/ml), and pcDNA-circSAMD4A (cat. no. G04002, concentration: 108 TU/ml) were purchased from Shanghai GenePharma Co., Ltd. The sequences of miR-29c-3p mimics were: (5′-3′) sense UAGCACCAUUUGAAAUCGGUUA, and antisense ACCGAUUUCAAAUGGUGCUAUU; mir-29c-3p inhibitor: (5′-3′) UAACCGAUUUCAAAUGGUGCUA; sh-circ: (5′-3′) AGCACAAGTACAAGAATCATT; miRNA mimic NC: (5′-3′) sense UUUGUACUACACAAAAGUACUG and (5′-3′) antisense CAGUACUUUUGUGUAGUACAAA; miRNA inhibitor NC: (5′-3′) CAGUACUUUUGUGUAGUACAAA. The cell transfection was performed using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to manufacturer's instructions for 48 h at 37°C. Then, cells were treated with 1 mM MPP+ solution for 24 h at 37°C.

The binding site seed regions of miR-29c-3p and 3′-UTR of circSAMD4 were determined using TargetScan (release 7.2, http://www.targetscan.org). A pmirGLO vector (Guangzhou RiboBio Co., Ltd.) containing wild-type (WT) and mutant (MUT) 3′-UTR of circSAMD4A was constructed according to the predicted binding sites. Then, cells were co-transfected with the circSAMD4A 3′-UTR-WT reporter vector or 3′-UTR-MUT reporter vector using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) for 48 h. Subsequently, a dual-reporter luciferase assay system in a Tecan SpectraFluorPlus plate-reader (Tecan Group, Ltd.) was employed to determine luciferase activity.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A